📊 BDTB Key Takeaways
Investment Thesis
Bodhi Tree Biotechnology is a pre-revenue shell company with severe operational losses and negative cash flow, indicating it is not yet a functioning business. The company is rapidly burning cash despite minimal operations, with negative ROE and ROA suggesting shareholder value destruction. Without demonstrated revenue generation capability or clear path to profitability, this represents a speculative investment with substantial going concern risk.
BDTB Strengths
- Positive stockholders equity of $66.2K provides minimal equity cushion
- Low debt burden with zero long-term debt reduces leverage risk
- Cash position of $47.4K provides short-term runway for operations
BDTB Risks
- Zero revenue generation with no demonstrated business model or market traction
- Negative operating cash flow of -$62K indicates unsustainable cash burn rate
- Severely negative returns on equity (-80%) and assets (-76%) demonstrating value destruction
- Pre-revenue status suggests high risk of failure and capital depletion within 12-18 months at current burn rate
- No insider activity in past 90 days indicates lack of management confidence
Key Metrics to Watch
- Revenue generation and path to profitability
- Monthly cash burn rate and runway remaining
- Operating cash flow trend and improvement toward breakeven
- Form 4 filings indicating insider buying confidence
BDTB Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BDTB Profitability Ratios
BDTB vs Default Sector
How Bodhi Tree Biotechnology Inc compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BDTB Balance Sheet & Liquidity
BDTB 5-Year Financial Trend
5-Year Trend Summary: Bodhi Tree Biotechnology Inc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.00 indicates the company is currently unprofitable.
BDTB Growth Metrics (YoY)
BDTB Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$52.9K | $0.00 |
| Q3 2025 | $5.0K | $9.6K | $0.00 |
| Q2 2025 | $5.0K | -$116 | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BDTB Capital Allocation
BDTB SEC Filings
Access official SEC EDGAR filings for Bodhi Tree Biotechnology Inc (CIK: 0002041531)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BDTB
What is the AI rating for BDTB?
Bodhi Tree Biotechnology Inc (BDTB) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BDTB's key strengths?
Positive stockholders equity of $66.2K provides minimal equity cushion. Low debt burden with zero long-term debt reduces leverage risk.
What are the risks of investing in BDTB?
Zero revenue generation with no demonstrated business model or market traction. Negative operating cash flow of -$62K indicates unsustainable cash burn rate.
What is BDTB's revenue and growth?
Bodhi Tree Biotechnology Inc reported revenue of $0.0.
Does BDTB pay dividends?
Bodhi Tree Biotechnology Inc does not currently pay dividends.
Where can I find BDTB SEC filings?
Official SEC filings for Bodhi Tree Biotechnology Inc (CIK: 0002041531) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BDTB's EPS?
Bodhi Tree Biotechnology Inc has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.